

CYTOKINETICS INC  
Form 8-K  
September 13, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**  
**Date of Report (Date of earliest event reported): September 13, 2006**  
**CYTOKINETICS, INCORPORATED**  
(Exact name of registrant as specified in its charter)

**DELAWARE**

**000-50633**

**94-3291317**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(IRS Employer  
Identification No.)

**280 East Grand Avenue**  
**South San Francisco, California 94080**

(Address of principal executive offices, including zip code)

**650-624-3000**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 8.01. OTHER EVENTS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**ITEM 8.01. OTHER EVENTS.**

Cytokinetics, Incorporated issued a press release announcing data from a first-in-humans Phase I clinical trial evaluating CK-1827452, a novel cardiac myosin activator, administered intravenously. Data from this double-blind, randomized, placebo-controlled, dose-escalation Phase I clinical trial of CK-1827452 were presented at a session entitled "Recent and Late Breaking Trials" at the 10<sup>th</sup> Annual Meeting of the Heart Failure Society of America in Seattle, Washington. This clinical trial was conducted to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of a six-hour infusion of CK-1827452 in healthy volunteers. A copy of the press release is being filed with this Current Report on Form 8-K as Exhibit 99.1, and is hereby incorporated by reference under this Item 8.01.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

**(c) Exhibits.**

The following Exhibit is filed as part of this Current Report on Form 8-K:

**Exhibit No. Description**

99.1 Presentation of Phase I Clinical Trial Data Press Release, dated September 13, 2006.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CYTOKINETICS, INCORPORATED**

By: /s/ Sharon Surrey Barbari  
Sharon Surrey-Barbari  
*Senior Vice President, Finance and  
Chief Financial Officer*

Date: September 13, 2006

3

---

**Table of Contents**

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Presentation of Phase I Clinical Trial Data Press Release, dated September 13, 2006.

4